SARS-CoV-2 seroconversion among 4040 Egyptian healthcare workers in 12 resource-limited healthcare facilities: A prospective cohort study.
COVID-19
SARS-CoV-2
asymptomatic
cohort
healthcare workers
seroconversion
Journal
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
ISSN: 1878-3511
Titre abrégé: Int J Infect Dis
Pays: Canada
ID NLM: 9610933
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
09
12
2020
revised:
31
12
2020
accepted:
10
01
2021
pubmed:
24
1
2021
medline:
24
4
2021
entrez:
23
1
2021
Statut:
ppublish
Résumé
We examined Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) seroconversion incidence and risk factors 21 days after baseline screening among healthcare workers (HCWs) in a resource-limited setting. A prospective cohort study of 4040 HCWs took place at 12 university healthcare facilities in Cairo, Egypt; April-June 2020. Follow-up exposure and clinical data were collected through online survey. SARS-CoV-2 testing was done using rapid IgM and IgG serological tests and reverse transcriptase-polymerase chain reaction (RT-PCR) for those with positive serology. Cox proportional hazards modelling was used to estimate adjusted hazard ratios (HR) of seroconversion. 3870/4040 (95.8%) HCWs tested negative for IgM, IgG and PCR at baseline; 2282 (59.0%) returned for 21-day follow-up. Seroconversion incidence (positive IgM and/or IgG) was 100/2282 (4.4%, 95% CI:3.6-5.3), majority asymptomatic (64.0%); daily hazard of 0.21% (95% CI:0.17-0.25)/48 746 person-days of follow-up. Seroconversion was: 4.0% (64/1596; 95% CI:3.1-5.1) among asymptomatic; 5.3% (36/686; 95% CI:3.7-7.2) among symptomatic HCWs. Seroconversion was independently associated with older age; lower education; contact with a confirmed case >15 min; chronic kidney disease; pregnancy; change/loss of smell; and negatively associated with workplace contact. Most seroconversions were asymptomatic, emphasizing need for regular universal testing. Seropositivity was three-fold that observed at baseline. Cumulative infections increased nationally by a similar rate, suggesting HCW infections reflect community not nosocomial transmission.
Sections du résumé
BACKGROUND
BACKGROUND
We examined Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) seroconversion incidence and risk factors 21 days after baseline screening among healthcare workers (HCWs) in a resource-limited setting.
METHODS
METHODS
A prospective cohort study of 4040 HCWs took place at 12 university healthcare facilities in Cairo, Egypt; April-June 2020. Follow-up exposure and clinical data were collected through online survey. SARS-CoV-2 testing was done using rapid IgM and IgG serological tests and reverse transcriptase-polymerase chain reaction (RT-PCR) for those with positive serology. Cox proportional hazards modelling was used to estimate adjusted hazard ratios (HR) of seroconversion.
RESULTS
RESULTS
3870/4040 (95.8%) HCWs tested negative for IgM, IgG and PCR at baseline; 2282 (59.0%) returned for 21-day follow-up. Seroconversion incidence (positive IgM and/or IgG) was 100/2282 (4.4%, 95% CI:3.6-5.3), majority asymptomatic (64.0%); daily hazard of 0.21% (95% CI:0.17-0.25)/48 746 person-days of follow-up. Seroconversion was: 4.0% (64/1596; 95% CI:3.1-5.1) among asymptomatic; 5.3% (36/686; 95% CI:3.7-7.2) among symptomatic HCWs. Seroconversion was independently associated with older age; lower education; contact with a confirmed case >15 min; chronic kidney disease; pregnancy; change/loss of smell; and negatively associated with workplace contact.
CONCLUSIONS
CONCLUSIONS
Most seroconversions were asymptomatic, emphasizing need for regular universal testing. Seropositivity was three-fold that observed at baseline. Cumulative infections increased nationally by a similar rate, suggesting HCW infections reflect community not nosocomial transmission.
Identifiants
pubmed: 33484863
pii: S1201-9712(21)00048-5
doi: 10.1016/j.ijid.2021.01.037
pmc: PMC7817419
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
534-542Informations de copyright
Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Références
Lancet Infect Dis. 2020 Sep;20(9):1051-1060
pubmed: 32539986
Nat Med. 2020 Jul;26(7):1033-1036
pubmed: 32398876
Am J Epidemiol. 2021 Jan 4;190(1):161-175
pubmed: 32870978
J Clin Microbiol. 2020 Jul 23;58(8):
pubmed: 32381641
JAMA Intern Med. 2020 Oct 1;180(10):1356-1362
pubmed: 32808970
Pathog Dis. 2020 Apr 1;78(3):
pubmed: 32510562
Lancet. 2020 Jul 25;396(10246):e6-e7
pubmed: 32653078
Lancet Infect Dis. 2020 Sep;20(9):1034-1042
pubmed: 32422204
Int J Epidemiol. 2021 Mar 3;50(1):50-61
pubmed: 33094320
Lancet Public Health. 2020 Sep;5(9):e475-e483
pubmed: 32745512
Mayo Clin Proc. 2020 Aug;95(8):1621-1631
pubmed: 32753137
PLoS Med. 2020 Oct 1;17(10):e1003358
pubmed: 33001967
Lancet Respir Med. 2020 Sep;8(9):885-894
pubmed: 32717210
Clin Infect Dis. 2020 Nov 19;71(16):2027-2034
pubmed: 32221519
PLoS Pathog. 2020 Sep 24;16(9):e1008817
pubmed: 32970782
Lancet Infect Dis. 2021 Feb;21(2):168
pubmed: 32553187
Emerg Infect Dis. 2021 Jan;27(1):
pubmed: 33021927
Cochrane Database Syst Rev. 2020 Jun 25;6:CD013652
pubmed: 32584464
JAMA. 2020 Jun 16;323(23):2424-2425
pubmed: 32407440
Nat Med. 2020 Jun;26(6):845-848
pubmed: 32350462
J Clin Virol. 2020 Sep;130:104575
pubmed: 32805631
Nat Microbiol. 2020 Dec;5(12):1598-1607
pubmed: 33106674